Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Relacorilant by Corcept Therapeutics for Cushing's Syndrome: Likelihood of Approval
Relacorilant is under clinical development by Corcept Therapeutics and currently in Phase III for Cushing's Syndrome. According to GlobalData, Phase...
Relacorilant by Corcept Therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval
Relacorilant is under clinical development by Corcept Therapeutics and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According...
Relacorilant by Corcept Therapeutics for Prostate Cancer: Likelihood of Approval
Relacorilant is under clinical development by Corcept Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Corcept Therapeutics's Relacorilant?
Relacorilant is a small molecule commercialized by Corcept Therapeutics, with a leading Phase III program in Cushing's Syndrome. According to...